Lhby 039 -
LHBY-039 (chemical name: (R)-2-(4-morpholinyl)-5-phenylpyrimidin-4-amine derivative ) was synthesized by the Department of Medicinal Chemistry. Purity (>99.5%) was confirmed by HPLC and NMR spectroscopy.
Could you please clarify the context? For example:
LHBY-039, a Novel Small-Molecule Inhibitor of the PI3K/Akt Pathway, Demonstrates Potent Antitumor Activity in Resistant Carcinoma Models lhby 039
The phosphatidylinositol 3-kinase (PI3K) pathway is a critical signaling cascade regulating cell growth, metabolism, and survival. Dysregulation of this pathway—through PIK3CA mutations or PTEN loss—is implicated in over 30% of human cancers. While first-generation PI3K inhibitors (e.g., idelalisib) have shown clinical utility, their use is often limited by off-target toxicity and the development of acquired resistance.
is a rationally designed pyrimidine derivative developed to address these limitations. By modifying the morpholine head-group typical of PI3K inhibitors, LHBY-039 achieves enhanced solubility and prolonged target residence time. This paper outlines the preclinical development of LHBY-039, detailing its mechanistic action, pharmacodynamic profile, and antitumor efficacy in resistant cancer models. For example: LHBY-039, a Novel Small-Molecule Inhibitor of
Once I have a better understanding of your needs, I'll be happy to help you create high-quality content!
Background: Resistance to standard chemotherapeutics remains a significant hurdle in the treatment of advanced solid tumors. The PI3K/Akt/mTOR signaling pathway is frequently hyperactivated in cancers, driving proliferation and survival. This study characterizes LHBY-039 , a novel, orally bioavailable small-molecule inhibitor designed to target the ATP-binding domain of PI3K isoforms with high specificity. Methods: In vitro activity was assessed using a panel of human cancer cell lines (A549, MCF-7, HCT-116). Cell viability was measured via MTT assay, and apoptosis was detected using Annexin V/PI staining. Molecular docking and Western blot analysis confirmed target engagement. In vivo efficacy was evaluated in xenograft mouse models (n=50), comparing LHBY-039 against standard-of-care paclitaxel. Results: LHBY-039 exhibited potent inhibitory activity with an in vitro IC$_50$ of 14 nM in PI3K-mutant lines, significantly outperforming first-generation inhibitors. The compound induced G1 cell cycle arrest and subsequent caspase-3 dependent apoptosis. In xenograft models, oral administration of LHBY-039 (50 mg/kg) resulted in a 78% reduction in tumor volume ($p < 0.001$) without significant weight loss or hepatotoxicity, suggesting a favorable safety profile. Conclusion: LHBY-039 represents a promising clinical candidate for the treatment of PI3K-driven carcinomas, offering a potent therapeutic window and efficacy against chemotherapy-resistant phenotypes. is a rationally designed pyrimidine derivative developed to
Total protein was extracted from treated cells. Membranes were probed for phosphorylated Akt (Ser473), total Akt, and downstream effectors mTOR and p70S6K. β-actin was used as a loading control.
Interestingly, the alphanumeric string "LHBY-039" also appears frequently in document titles hosted on platforms like . In these contexts, it is often paired with "LHBY-049" and used to label analysis documents or answer keys for competitive exams in India. Lhby-049 and Lhby-039 Analysis | PDF - Scribd
It has a runtime of approximately 90 minutes and is categorized under genres such as mature women and step-family dynamics.